Payment overview · 2025
General Payments
$5,564.43
238 reported records · 34 companies
Healthcare provider profile · identity verified
Anna Litvak, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · PEABODY, MA · NPI 1093784688
Verified facts
What the public records show
CMS Open Payments records show Anna Litvak, M.D. received $5,564.43 in general payments during 2025 across 238 reported records.
ABBVIE INC. accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 50 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Nuplazid, Nurtec Odt, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Nuplazid by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MAYZENT as an associated drug or biological on 26 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mayzent by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $1,093.12 | 19.6% | 44 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $321.79 | 5.8% | 22 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $312.22 | 5.6% | 13 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $284.74 | 5.1% | 7 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $283.75 | 5.1% | 11 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $274.11 | 4.9% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $273.30 | 4.9% | 18 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $261.44 | 4.7% | 9 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $229.66 | 4.1% | 12 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $208.17 | 3.7% | 13 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $189.62 | 3.4% | 6 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $187.61 | 3.4% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $168.14 | 3.0% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $165.99 | 3.0% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $142.58 | 2.6% | 5 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $128.15 | 2.3% | 5 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $111.99 | 2.0% | 5 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $106.53 | 1.9% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $98.04 | 1.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $93.77 | 1.7% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $89.46 | 1.6% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $79.67 | 1.4% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $70.84 | 1.3% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$69.18 | 1.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $53.08 | 0.9% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $50.64 | 0.9% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $42.27 | 0.8% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $33.87 | 0.6% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.70 | 0.5% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.57 | 0.5% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $23.85 | 0.4% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $23.01 | 0.4% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $20.87 | 0.4% | 1 | 2025 |
| Life Molecular Imaging Ltd | Unresolved — no canonical attribution shown | $16.70 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,442.69 | 236 |
| Education | $121.74 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $613.50 | 22 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $427.07 | 20 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $410.88 | 19 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $304.90 | 12 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $273.30 | 18 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $270.79 | 19 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $262.64 | 12 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $249.77 | 17 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $208.17 | 13 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $197.86 | 8 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $187.61 | 10 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $177.46 | 6 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $174.76 | 9 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $143.20 | 7 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $142.98 | 5 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $142.58 | 5 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $128.15 | 5 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $111.99 | 5 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $106.53 | 4 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $92.91 | 3 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $92.51 | 4 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $91.86 | 4 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $91.02 | 2 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $90.07 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $89.46 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $79.67 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $75.84 | 3 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $63.39 | 2 | 2025 |
Source payment records
|
|||||
| Apokyn Normalized: apokyn |
Drug | MDD US Operations, LLC | $54.90 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $53.08 | 2 | 2025 |
Source payment records
|
|||||
| RYTARY Normalized: rytary |
Drug | Amneal Pharmaceuticals LLC | $51.00 | 3 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $50.52 | 2 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $49.76 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $47.38 | 2 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $43.78 | 1 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $43.25 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $40.26 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $39.75 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $33.87 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $28.70 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $28.41 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $27.57 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $22.20 | 1 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| AVONEX Normalized: avonex |
Biological | Biogen, Inc. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| NEURACEQ Normalized: neuraceq |
Drug | Life Molecular Imaging Ltd | $16.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 46 | exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
46 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | MAYZENT open payments reported associated product |
CMS Open Payments — General Payments 26 supporting records · 26 recipient NPIs · example record 1200006493 |
Mayzent · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 405 | 104 |
| Levetiracetam | Levetiracetam | 242 | 49 |
| Gabapentin | Gabapentin | 235 | 50 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 231 | 57 |
| Galantamine Er | Galantamine Hbr | 208 | 47 |
| Memantine Hcl | Memantine Hcl | 166 | 48 |
| Divalproex Sodium | Divalproex Sodium | 130 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 126 | 19 |
| Lamotrigine | Lamotrigine | 118 | 15 |
| Trazodone Hcl | Trazodone Hcl | 88 | 27 |
| Rizatriptan | Rizatriptan Benzoate | 82 | 18 |
| Aimovig Autoinjector | Erenumab-Aooe | 69 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 66 | 12 |
| Sertraline Hcl | Sertraline Hcl | 63 | 13 |
| Topiramate | Topiramate | 57 | 12 |
| Phenobarbital | Phenobarbital | 51 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 48 | suppressed |
| Botox | Onabotulinumtoxina | 46 | 17 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 45 | suppressed |
| Pregabalin | Pregabalin | 45 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 42 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 41 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 39 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 36 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 35 | suppressed |
| Carbamazepine Er | Carbamazepine | 34 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 34 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | 12 |
| Emgality Pen | Galcanezumab-Gnlm | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Lacosamide | Lacosamide | 26 | suppressed |
| Entacapone | Entacapone | 25 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Dalfampridine Er | Dalfampridine | 24 | suppressed |
| Prednisone | Prednisone | 24 | suppressed |
| Carbidopa | Carbidopa | 23 | suppressed |
| Levetiracetam Er | Levetiracetam | 21 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 21 | suppressed |
| Ubrelvy | Ubrogepant | 21 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Neupro | Rotigotine | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Zonisamide | Zonisamide | 19 | suppressed |
| Alprazolam | Alprazolam | 17 | 16 |
| Baclofen | Baclofen | 17 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Mayzent | Siponimod | 15 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 15 | suppressed |
| Tegretol | Carbamazepine | 14 | suppressed |
| Copaxone | Glatiramer Acetate | 13 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Zolmitriptan | Zolmitriptan | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Aubagio | Teriflunomide | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Teriflunomide | Teriflunomide | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,564.43 · 238 records | ABBVIE INC. | AJOVY, AMYVID, AUSTEDO XR, AVONEX, Apokyn, BOTOX, BRIUMVI, Bafiertam, Briviact, CREXONT, ENHERTU, General - Pain Management, General - Therapies, Gocovri, HORIZANT, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, LEQEMBI, Mavenclad, NEURACEQ, NUPLAZID, NURTEC ODT, Nayzilam, Ocrevus Zunovo, PONVORY, QULIPTA, Qelbree, REXULTI, RYTARY, Rystiggo, SKYCLARYS, Symbravo, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, Xeomin, ZAVZPRET, ZEPBOUND, ZEPOSIA, Zilbrysq | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error